Research Activity
Endeavor’s $132.5 Million Funding Accelerates Fibrotic Lung and Solid Tumor Therapeutic Development
Endeavor, funding, fibrotic lung, solid tumors, therapeutic development, medical research, healthcare innovation.
Biogen’s Leqembi Gains Momentum: A Steady Pace in Market Growth
Biogen, Leqembi, Alzheimer’s disease, clinical trials, FDA approval, market growth, steady pace, neurology, healthcare, pharmaceuticals.
Day One Outshines Novartis: FDA Approves Ojemda for Wider Pediatric Brain Tumor Treatment
Day One, Novartis, FDA, Ojemda, pediatric brain tumor, cancer treatment, clinical trials, pharmaceutical industry.
Xaira: The Billion-Dollar AI-Powered Drug Discovery Startup Revolutionizing Healthcare
Xaira, AI, drug discovery, healthcare, startup, funding, billion-dollar, revolutionizing, pharmaceuticals, biotechnology.
Revolutionizing Research and Development: Xaira Unveils AI-Driven Platform with $1B Funding and Former Genentech Leaders
AI-Powered Xaira, $1B funding, Genentech executives, R&D transformation, biotechnology innovation, artificial intelligence in research, life sciences advancement.
Neurocrine Biosciences and Takeda’s Collaborative Drug Shows Promising Results in Phase II Clinical Trial for Depression
Neurocrine Biosciences, Takeda, drug candidate, Phase II clinical trial, depression, promising results.
BenevolentAI Downsizes Operations, Cuts 30% of Workforce Amidst Funding Challenges
BenevolentAI, layoffs, workforce reduction, funding gap, US site closure, AI research, drug discovery
Neurocrine Biosciences and Takeda’s Collaborative Depression Program Achieves Mid-Stage Success
Neurocrine Biosciences, Takeda, depression program, mid-stage success, clinical trials, mental health, pharmaceutical collaboration.
BenevolentAI Announces Significant Restructuring with Workforce Reduction and US Office Closure
BenevolentAI, restructuring, workforce reduction, US office closure, reset, artificial intelligence, biotechnology, drug discovery
FDA Rejects Abeona’s PZ-CEL Topical Gene Therapy, Delaying Further Progress
Abeona, PZ-CEL, topical gene therapy, FDA, rejection, delay, clinical trials, EB-101, Epidermolysis Bullosa